ArticleTransplantation2010
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
Article in Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 145 citations in OpenAlex.
- Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.Diabetes care · 2020Trial
- Profiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immunosuppressive agents in diabetes treatment: Hope or despair?World journal of diabetes · 2025Review
- Immune Evasion in Stem Cell-Based Diabetes Therapy-Current Strategies and Their Application in Clinical Trials.Biomedicines · 2025Review
- From Edmonton to Lantidra and beyond: immunoengineering islet transplantation to cure type 1 diabetes.Frontiers in transplantation · 2025Review
- Controlling spheroid attachment improves pancreatic beta cell differentiation from human iPS cells.In vitro cellular & developmental biology. Animal · 2024Article
- Evaluating Global and Temporal Trends in Pancreas and Islet Cell Transplantation: Public Awareness and Engagement.Clinics and practice · 2024Article
- Evaluation of Pancreatic β-cell Differentiation Efficiency of Human iPSC Lines for Clinical UseCurrent stem cell research & therapy · 2024Article
- Pancreatic islet transplantation: current advances and challenges.Frontiers in immunology · 2024Review
- Enrichment of stem cell-derived pancreatic beta-like cells and controlled graft size through pharmacological removal of proliferating cells.Stem cell reports · 2023Article
- A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Anti-thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival.Xenotransplantation · 2021Article
- Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.Acta biomaterialia · 2021Review
- Examination of the Igls Criteria for Defining Functional Outcomes of β-cell Replacement Therapy: IPITA Symposium Report.The Journal of clinical endocrinology and metabolism · 2021Article
- Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes.Frontiers in endocrinology · 2021Review
- A potential drug in the armamentarium of post-cardiac transplantation immunosuppression: belatacept.Indian journal of thoracic and cardiovascular surgery · 2020Review
- Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.Diabetologia · 2020Review
- Pancreatic islet transplantation: toward definitive treatment for diabetes mellitus.Global health & medicine · 2020Review
- Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells.Frontiers in bioengineering and biotechnology · 2020Review
- De Novo Belatacept in a Kidney-After-Heart Transplant Recipient.Transplantation direct · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe applicability of islet transplantation as treatment for type 1 diabetes is limited by long-term graft dysfunction, immunosuppressive drug toxicity, need for multiple donors, and increased risk of allosensitization. We describe two immunosuppressive regimens based on the costimulation blocker belatacept (BELA) or the antileukocyte functional antigen-1 antibody efalizumab (EFA), which permit long-term islet allograft survival and address some of these concerns.
methodsTen patients with type 1 diabetes with hypoglycemic unawareness received intraportal allogeneic islet transplants. Immunosuppression consisted of antithymocyte globulin induction and maintenance with sirolimus or mycophenolate and BELA (n=5) or EFA (n=5).
resultsAll five BELA-treated patients achieved independence after single transplants; one resumed partial insulin use 305 days after transplant but is now independent after a second transplant. All five patients treated with EFA achieved independence after one (3/5) or two (2/5) islet transplants and remained independent while on EFA (392-804 days). After EFA was discontinued because of withdrawal of the drug from the market, two patients resumed intermittent insulin use; the others remain independent. No patient in either group developed significant side effects related to the study drugs, and none have been sensitized to alloantigens. All have stable renal function.
conclusionsThese two novel immunosuppressive regimens are effective, well tolerated, and the first calcineurin inhibitor/steroid-sparing islet protocols resulting in long-term insulin independence. Although EFA is no longer available for clinical use, these early results demonstrate that a regimen using BELA may be an effective alternative to improve graft function and longevity while minimizing renal and β-cell toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.